A phase II randomized placebo-controlled study of fisetin and exercise to mitigate chemotherapy-related functional decline in postmenopausal women with early breast cancer (PROFFi).
Jingran Ji(Northwestern University), Mina S. Sedrak(University of California, Los Angeles), Sandra A. Finestone(Consumers Union), Heather L. McArthur(Southwestern Medical Center), Hyman B. Muss(University of North Carolina at Chapel Hill), Catherine M. Crespi(University of California, Los Angeles), Poorni Manohar(Southwestern Medical Center), Joseph D. Olivera(University of California, Los Angeles), Marla Lipsyc-Sharf(UCLA Health), Laura Petersen(APLA Health), Patricia A. Spears(University of North Carolina at Chapel Hill), Yuliya Zektser(University of California, Los Angeles), Kirsten K. Ness(St. Jude Children's Research Hospital), George A. Kuchel(UConn Health), Arash Naeim(University of California, Los Angeles), Beverly Canin(City Of Hope National Medical Center), A. Saleem(University of California, Los Angeles), Yara Abdou(University of North Carolina at Chapel Hill), Kelly S. Synold(University of California, Los Angeles), Mylin A. Torres(Emory University)
Cited by 2
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991
Clinical Practice Guideline: Sudden Hearing Loss (Update)
|Otolaryngology|2019|918